Table 1.
Basic characteristics of inclusion in the study.
| Study | Sample size | Sex | Age(Years) | Duration of | Course of | Intervention | Outcomes | Adverse | ||
|---|---|---|---|---|---|---|---|---|---|---|
| T/C | (M/F) | Range,mean | diabetes(Years) | treatment | T | C | reactions | |||
| Xiong et al., 2013 | 30/30 | T: 17/13 C: 18/12 |
T: 55.8 ± 7.4 C: 56.5 ± 7.3 |
T: 7.7 ± 1.7 C: 7.6 ± 1.8 |
3 weeks | Salvianolate (200 mg, ivgtt, qd)+ conventional treament | Conventional treament | Scr, UAER | None | |
| Zhang and Li, 2014 | 45/45 | 50/40 | T: 48.9 ± 10.1 C: 49.4 ± 9.6 |
T: 8.49 ± 1.6 C: 8.51 ± 1.4 |
2 weeks | Salvianolate (100 mg, ivgtt, qd)+ conventional treament | Conventional treament | SOD, MDA, ACR | Not reported | |
| Xu, 2014 | 30/30 | T: 18/12 C: 19/11 |
T: 56.34 ± 6.06 C: 55.81 ± 7.24 |
T: 6.25 ± 5.07 C: 6.69 ± 4.62 |
4 weeks | Salvianolate (200 mg, ivgtt, qd)+ conventional treament | Conventional treament | Scr, UAER | Not reported | |
| Liu et al., 2014 | 30/30 | T: 14/16 C: 17/13 |
T: 65.12 ± 9.83 C: 65.4 ± 9.6 |
T: 12.91 ± 2.12 C: 12.42 ± 2.28 |
2 weeks | Salvianolate (200 mg, ivgtt, qd)+ conventional treament | Conventional treament | Scr, BUN, UAER | T: 1 case of Palpitations during infusion C: None |
|
| Lu et al., 2014 | 33/31 | T: 16/17 C: 16/15 |
T: 56.16 ± 9.09 C: 54.70 ± 9.26 |
– – |
2 weeks | Salvianolate (200 mg, ivgtt, qd)+ Insulin therapy | Insulin therapy | hs-CRP, IL-6 | Not reported | |
| Zhao et al., 2015 | 45/45 | T: 24/21 C: 24/21 |
T: 63.4 ± 9.80 C: 63.0 ± 11.1 |
T: 7.1 ± 2.4 C: 7.3 ± 1.4 |
4 weeks | Salvianolate (200 mg, ivgtt, qd)+ conventional treament | Conventional treament | Scr, BUN, UAER, Clinical efficacy | None | |
| Zhang et al., 2015 | 42/42 | T: 23/19 C: 25/17 |
T: 39~72 C: 41~71 |
T: 5.8 ± 1.4 C: 5.7 ± 1.1 |
2 weeks | Salvianolate (200 mg, ivgtt, qd)+ conventional treament | Conventional treament | UAER, hs-CRP, IL-6 | Not reported | |
| Ma and Zhao, 2015 | 59/59 | T: 29/30 C: 27/32 |
T: 53~78 C: 51~79 |
T: 12.3 ± 3.8 C: 12.5 ± 2.8 |
2 weeks | Salvianolate (200 mg, ivgtt, qd)+ conventional treament | Conventional treament | hs-CRP, IL-6 | Not reported | |
| Fu and Shao, 2018 | 38/38 | T: 22/16 C: 18/20 |
T: 45~75 C: 42~74 |
T: 5.98 ± 2.27 C: 6.04 ± 2.03 |
2 weeks | Salvianolate (100 mg, ivgtt, qd)+ Irbesartan (150 mg, po, qd) | Irbesartan (150mg, po, qd) | Scr, BUN, Clinical efficacy, hs-CRP, IL-6, MDA, SOD, 24h Upro, ACR | None | |
| Chen et al., 2018 | 60/60 | T: 39/21 C: 38/22 |
T: 68.82 ± 8.63 C: 68.45 ± 8.35 |
T: 6.54 ± 2.64 C: 6.65 ± 2.15 |
2 weeks | Salvianolate (200 mg, ivgtt, qd)+ Losartan potassium (50 mg, po, qd) | Losartan potassium (50mg, po, qd) | Scr, BUN, Clinical efficacy, hs-CRP, IL-6, 24h Upro | Not reported | |
| Liang and Wang, 2019 | 47/47 | T: 27/20 C: 26/21 |
T: 57.34 ± 6.28 C: 57.15 ± 6.34 |
T: 4.87 ± 2.41 C: 4.95 ± 2.36 |
2 weeks | Salvianolate (200 mg, ivgtt, qd)+ Irbesartan (150 mg, po, qd) | Irbesartan (150mg, po, qd) | Scr, BUN, Clinical efficacy, SOD, MDA, 24h Upro | Not reported | |
| Chen et al., 2019 | 57/57 | T: 33/24 C: 34/23 |
T: 58.41 ± 3.87 C: 57.25 ± 3.64 |
T: 4.93 ± 1.21 C: 4.85 ± 1.12 |
2 weeks | Salvianolate (200 mg, ivgtt, qd)+ conventional treament | conventional treament | Scr, BUN, Clinical efficacy, UAER | None | |
T, treatment group; C, control group; M, male; F, female; Scr, serum creatinine; UAER, urinary albumin excretion rate; BUN, blood urea nitrogen; SOD, superoxide dismutase; MDA, malondialdehyde; hs-CRP, hypersensitive C-reactive protein; IL-6, Interleukin-6; 24h Upro, 24-hour urinary protein; ACR, albumin-to-creatinine ratio.